Sentry Investment Management LLC increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,248 shares of the life sciences company’s stock after acquiring an additional 738 shares during the period. Sentry Investment Management LLC’s holdings in Illumina were worth $2,458,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of the stock. Bronfman E.L. Rothschild L.P. increased its holdings in Illumina by 23.8% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 2,182 shares of the life sciences company’s stock worth $477,000 after acquiring an additional 420 shares during the period. EFG Asset Management Americas Corp. bought a new stake in Illumina during the 4th quarter worth approximately $401,000. Connable Office Inc. bought a new stake in Illumina during the 4th quarter worth approximately $215,000. Sigma Planning Corp bought a new stake in Illumina during the 4th quarter worth approximately $221,000. Finally, LS Investment Advisors LLC increased its holdings in Illumina by 12.6% during the 4th quarter. LS Investment Advisors LLC now owns 3,580 shares of the life sciences company’s stock worth $782,000 after acquiring an additional 402 shares during the period. 92.04% of the stock is currently owned by institutional investors and hedge funds.
In other news, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $225.33, for a total value of $32,672.85. Following the completion of the sale, the senior vice president now owns 6,388 shares of the company’s stock, valued at approximately $1,439,408.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $226.55, for a total transaction of $283,187.50. Following the completion of the sale, the director now directly owns 9,088 shares of the company’s stock, valued at approximately $2,058,886.40. The disclosure for this sale can be found here. Insiders sold a total of 117,690 shares of company stock valued at $25,989,564 in the last ninety days. 0.89% of the stock is owned by corporate insiders.
A number of analysts recently weighed in on the stock. Deutsche Bank set a $275.00 target price on shares of Illumina and gave the stock a “buy” rating in a report on Tuesday, January 16th. Cowen upped their target price on shares of Illumina from $250.00 to $275.00 and gave the stock an “outperform” rating in a report on Monday, January 22nd. Leerink Swann boosted their price target on shares of Illumina from $250.00 to $276.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Morgan Stanley boosted their price target on shares of Illumina from $145.00 to $157.00 and gave the stock an “underweight” rating in a research note on Wednesday, January 31st. Finally, BTIG Research reissued a “hold” rating on shares of Illumina in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company. Illumina currently has a consensus rating of “Buy” and an average price target of $241.39.
Illumina, Inc. (NASDAQ ILMN) opened at $221.03 on Tuesday. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a 12 month low of $158.02 and a 12 month high of $248.97. The company has a market cap of $31,709.74, a P/E ratio of 44.56, a price-to-earnings-growth ratio of 2.87 and a beta of 0.92.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.22. Illumina had a net margin of 26.56% and a return on equity of 21.52%. The company had revenue of $778.00 million during the quarter, compared to analysts’ expectations of $752.04 million. During the same quarter in the prior year, the company earned $0.85 EPS. The firm’s revenue was up 25.7% on a year-over-year basis. sell-side analysts expect that Illumina, Inc. will post 4.59 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Sentry Investment Management LLC Has $2.46 Million Position in Illumina, Inc. (ILMN)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/13/sentry-investment-management-llc-has-2-46-million-position-in-illumina-inc-ilmn.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.